Ohm,

Thanks for the clarification. The larger question I return to is how much treating physicians look at therapies under development that don’t come from big pharma.

I have owned or considered owning, in addition to Cytodyn, humanigen, Synairgen, Valneva, Capricor, and Biocryst.

I was interested but passed on Mesoblast and relief therapeutics and would have bought oncoimmune were it not privately held.

My point is that these all are small companies with, at least at one point, promising therapies, vaccines or anti-virals.

I wonder how inquisitive the physicians and advisers around POTUS are. New challenges require new solutions, but it appears many continue to look to the same BP resources.

Disappointing and injurious to patients in need.